Trifluridine With Tipiracil Lifts Survival in Refractory Gastric Cancer

作者
Peter Goodwin,Sarah K. Maxwell
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:40 (21): 66-66
标识
DOI:10.1097/01.cot.0000549562.60187.7d
摘要

gastric cancer: gastric cancerBARCELONA—A chemotherapy combination consisting of trifluridine with tipiracil showed a “clinically meaningful and statistically significant” improvement in overall survival and progression-free survival (PFS) compared with placebo in patients with heavily pretreated metastatic gastric cancer (mGC) refractory to standard therapies in the randomized phase III TAGS study reported at the ESMO World Congress on Gastrointestinal Cancer 2018 (Abstract LBA-002). “The TAGS study has shown in a randomized phase III setting that trifluridine-tipiracil is an available option for treating patients with gastric or gastroesophageal cancer in the metastatic refractory setting,” said lead author Josep Tabernero, MD, PhD, Chair of Medical Oncology at Vall d'Hebron University Hospital in Barcelona, Spain. Research Details Study results show that patients lived a median of 5.7 months when treated with the new combination compared with 3.6 months in the control group receiving best supportive care—a 2.1 months extension of life and a 31-percent reduction in the risk of death (HR=0.69). The researchers found that the safety profile was “predictable and manageable” with “no new safety signals” and concluded that the combination represented an effective treatment option for patients with heavily pretreated mGC. The TAGS study randomized 507 patients with mGC (including gastroesophageal junction cancer) who had at least two prior regimens, including fluoropyrimidine, platinum, taxane, irinotecan, or a HER2 inhibitor. The 170 patients in the control group were given a placebo plus best supportive care, while the experimental arm of 337 patients (randomized 2-to-1) were treated with a combination of the novel oral thymidine analog trifluridine together with the thymidine phosphorylase inhibitor tipiracil and best supportive care. “The study met the primary endpoint of increasing overall survival. Patients also benefit in long-term survival—in 1 year, for example,” said Tabernero. The study also observed an advantage in PFS that was statistically significant. “There were no differences in safety profile between the two arms in the number of patients who had to discontinue treatment because of treatment-emergent adverse events,” he noted. The safety profile in gastric cancer was found to coincide with documented toxicities in patients with metastatic colorectal cancer treated with trifluridine plus tipiracil. Discussion Points Tabernero told Oncology Times the data were clinically promising, “especially for this highly unmet need population” and that he hoped trifluridine with tipiracil would be approved by regulatory authorities for gastric cancer as it had already been “in more than 50 countries” for metastatic colorectal cancer. Commenting on the study findings David Cunningham, MD, FRCP, Consultant Medical Oncologist and Director of Clinical Research at the Royal Marsden Hospital in London, said the significant survival advantage among patients treated with the new combination was interesting and that it was another option. “When patients have gone through the standard treatment options—usually including 5-FU, a platinum drug, and a taxane—and they have progressed, we can think about offering them the possibility of trifluridine and tipiracil,” he explained. However, for clinical practice, Cunningham recommended that patients be assessed before receiving such treatment, especially as some were not likely to be fit for further therapy after failing three lines of treatment. “We need to be clear about this. This won't be for everybody. But for those patients who are still fit, have good organ function, and wish to explore the possibility of further treatment these drugs represent a genuine alternative,” he said. Cunningham concluded that trifluridine with tipiracil had emerged as an option for patients who had failed standard chemotherapy. “Other options include the checkpoint antibodies like nivolumab. But this represents a regimen that can help some patients.” Peter M. Goodwin and Sarah Maxwell are contributing writers. Learn About More Conferences Start looking ahead to 2019 hematology/oncology conferences by visiting the Oncology Times online conference listing at http://bit.ly/1B38kF4. Here you will find dates, locations, and links for more information.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顾矜的应助被科研通管家采纳,获得10
刚刚
刚刚
华仔的应助被科研通管家采纳,获得10
刚刚
刚刚
刚刚
充电宝的应助被科研通管家采纳,获得10
刚刚
科目三的应助被科研通管家采纳,获得10
1秒前
1秒前
今后的应助被科研通管家采纳,获得10
1秒前
Jun的应助被科研通管家采纳,获得10
1秒前
1秒前
2213170089完成签到 ,获得积分10
1秒前
123发布了新的文献求助10
3秒前
lizi完成签到 ,获得积分10
3秒前
3秒前
小水滴完成签到,获得积分10
4秒前
翰林路发布了新的文献求助10
4秒前
QUIET发布了新的文献求助10
4秒前
sssugar完成签到,获得积分10
5秒前
yaoenhao发布了新的文献求助10
5秒前
超帅从彤完成签到,获得积分10
5秒前
是寄竹吖发布了新的文献求助10
6秒前
lee完成签到 ,获得积分10
7秒前
betty孙发布了新的文献求助10
7秒前
7秒前
7秒前
刘谦发布了新的文献求助10
8秒前
英勇皮卡丘完成签到,获得积分10
9秒前
谨慎问玉完成签到 ,获得积分10
9秒前
10秒前
表弟慢热手的应助被LI采纳,获得30
11秒前
斯文的乐天完成签到,获得积分10
12秒前
miaoli0116完成签到,获得积分10
12秒前
12秒前
lirui_nicely完成签到,获得积分10
13秒前
13秒前
虚幻的靖儿完成签到 ,获得积分10
13秒前
14秒前
言默发布了新的文献求助10
14秒前
lx发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186480
求助须知:如何正确求助?哪些是违规求助? 9574861
关于积分的说明 21838499
捐赠科研通 7784154
什么是DOI,文献DOI怎么找? 3434775
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481565